Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.43 |
| ▸ | CNR2 | P34972 | 7/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | BID | P55957 | 2/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778663 | 0.91 | CNR2 (0.42) | CNR1CNR2PLA2G2APPARGPPARA | |
| SCHEMBL5212214 | 0.91 | PPARG (0.46) | PLA2G2APPARGPPARAKAT8 | |
| SCHEMBL6896241 | 0.90 | CNR1 (0.42) | CNR1CNR2PLA2G2APLA2G1BGPR55 | |
| SCHEMBL6776320 | 0.90 | PPARG (0.41) | CNR1CNR2PLA2G2APPARGGPR55 | |
| SCHEMBL6776234 | 0.90 | PLA2G2A (0.47) | PLA2G2APLA2G1BBCL2L1 | |
| SCHEMBL6776818 | 0.88 | PPARG (0.45) | PLA2G2APLA2G1BPPARGKAT8EP300 | |
| SCHEMBL6775148 | 0.88 | CNR1 (0.42) | CNR1CNR2PLA2G2APPARG | |
| SCHEMBL6782670 | 0.88 | ALDH1A1 (0.39) | CNR1CNR2PPARGPPARAKAT8 | |
| SCHEMBL6771775 | 0.88 | PPARG (0.39) | CNR1CNR2PPARGPPARAKAT8 | |
| SCHEMBL6778112 | 0.87 | PPARG (0.40) | CNR1CNR2PLA2G2APLA2G1BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |